scispace - formally typeset
W

Wi S. Lai

Researcher at National Institutes of Health

Publications -  50
Citations -  6900

Wi S. Lai is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Tristetraprolin & Zinc finger. The author has an hindex of 31, co-authored 49 publications receiving 6402 citations. Previous affiliations of Wi S. Lai include Howard Hughes Medical Institute & Research Triangle Park.

Papers
More filters
Journal ArticleDOI

Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin

TL;DR: Findings identify TTP as a component of a negative feedback loop that interferes with TNF-α production by destabilizing its messenger RNA, which represents a potential target for anti-TNF- α therapies.
Journal ArticleDOI

A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency

TL;DR: Treatment of young TTP-deficient mice with antibodies to tumor necrosis factor alpha (TNF alpha) prevented the development of essentially all aspects of the phenotype, indicating a role for TTP in regulating TNF alpha synthesis, secretion, turnover, or action.
Journal ArticleDOI

Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA.

TL;DR: It is shown here that TTP binding to the TNF-α ARE is dependent upon the integrity of both zinc fingers, since mutation of a single cysteine residue in either zinc finger to arginine severely attenuated the binding of TTP to theTNF- α ARE.
Journal ArticleDOI

Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability.

TL;DR: It is shown that TTP deficiency also results in increased cellular production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and increased stability of its mRNA, apparently secondary to decreased deadenylation.
Journal ArticleDOI

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

TL;DR: It is demonstrated that RAS can drive cell‐intrinsic PD‐L1 expression, thus presenting therapeutic opportunities to reverse the innately immunoresistant phenotype of RAS mutant cancers and a post‐transcriptional mechanism whereby oncogenic RAS signaling increases PD‐l1 expression.